FDA disallows Avastin as breast-cancer drug

Avastin is no longer approved for treating metastatic breast cancer because it exposes patients to dangerous side effects without any benefit, the U.S. Food and Drug Administration said Friday.

The FDA noted that Avastin’s risks include severely high blood pressure, bleeding, heart attacks, and perforations in such body parts as the nose, stomach, and intestines.

Read more: http://www.philly.com/philly/business/134159658.html#ixzz1eCV7CTP6